Telavancin is under review by FDA (NDA filed December 2006) for use in treating complicated skin and soft-tissue infections caused by gram-positive bacteria. The manufacturer is actively ...

Am J Health Syst Pharm. 2007;64(22):2335-2348. The efficacy of telavancin has been studied in several animal models of infection, including bacteremia, endocarditis, meningitis, and pneumonia ...